Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, “patent expiration” is often treated like background noise: something to monitor, maybe, when it becomes unavoidable. But the reality i…

Most teams don’t “miss” generic launches—they miss the timing.
In generic drug forecasting, being wrong by a few months can be the difference between capturing share and watching competitors lock in contracts, inventory, and payer conversations first…

Pharma has a talent problem—and it’s hiding in plain sight.
Most people look at the FDA Orange Book as a regulatory document. But if you’re a sourcing leader, a recruiter, or a business developer trying to find the people who actually move drug develop…

Biotech investors love “pipeline value,” but most portfolio rankings still miss the point.
A company can have a long list of programs and a compelling story—yet the capital allocation may be quietly inefficient. The reason is simple: not all R&D do…

The “Patent Cliff” Isn’t Just a Pharma Problem—It’s a Talent Problem.
If you think the next wave of biopharma disruption will be driven only by molecules, trials, and pipeline math, you’re missing a quieter force reshaping hiring: the patent cliff.
Whe…

Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
Overstocking branded drugs isn’t just a balance-sheet problem—it’s a cash-flow crisis waiting to happen.
When branded products face patent cliffs, exclusivi…

Big Pharma doesn’t just “restructure” when a patent cliff hits. It signals.
If you want to understand workforce shifts before they show up in earnings calls, look past the press releases and into the patent cliff events themselves. The hidden hiring si…

Biosimilar sourcing isn’t a procurement problem—it’s an IP strategy problem.
If you’re responsible for switching a portfolio from originator biologics to biosimilars, you already know the operational side: contracting, forecasting, tendering, supply as…

Pharma has a new playbook—and it’s not always about new science.
In a world where patients and payers are increasingly skeptical of “premium” drug prices, the industry is leaning on a familiar narrative: repurposed medicines deserve higher costs becaus…

Pharma recruiting is broken—at least when it comes to how most teams “find” talent.
They search for titles. They scan résumés. They ask for the same buzzwords. And they miss the real signal: who has actually shaped the science behind the next wave of d…